At the Symposium "Which target to protect and preserve lung health?" we talked about the management of patients with chronic lung diseases and new evidence in COVID-19 scientific research

Internationally renowned experts discussed the relationship between oxidative stress and lung health and the potential benefit of chronic therapy with antioxidant drugs in the prevention and treatment of acute and chronic lung diseases.

Milan, September 9th, 2020 – The Symposium, "WHICH TARGET TO PROTECT AND PRESERVE LUNG HEALTH?", sponsored by Zambon, was held this morning during the ERS International Congress 2020. World-renowned experts discussed high social-welfare impact lung diseases, such as COPD (Chronic Obstructive Pulmonary Disease) and IPF (Idiopathic Pulmonary Fibrosis), and some evidence that has emerged during the management of the global health emergency from SARS-COV-2 (COVID-19).

In particular, the scientific debate focused on the recent COVID-19 pandemic, and on the observation of the common denominator between COPD and IPF: oxidative stress, currently identified as a key element for understanding the onset and chronicity of various clinical conditions.

The COVID-19 epidemic has reconfirmed the importance of maintaining an effective protection system at the pulmonary level: the viral insult generates an imbalance between the antioxidant system and free radicals, which, if perpetuated, is one of the causes of post COVID fibrosis. An early restoration of this balance with antioxidant therapy is hoped to limit both the onset and the perpetuation of the damage.

The Symposium experts shared significant updates on oxidative stress and lung damage and discussed possible future developments in clinical research. A potential role of antioxidant therapy is the protection and preservation of lung function, for the frailest patients.